These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38365047)

  • 1. Bruton's tyrosine kinase ablation inhibits B cell responses and antibody production for the prevention of chronic rejection in cardiac transplantation.
    Han F; Shi X; Liao T; Zhang W; Ma M; Leng Q; Jiang W; Na N; Miao Y; Huang Z
    Clin Immunol; 2024 Apr; 261():109941. PubMed ID: 38365047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
    Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
    Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection.
    Liao T; Shi X; Han F; Wang Y; Zeng W; Liu R; Yan Z; Xia R; Huang Z; Xu J; Miao Y
    J Heart Lung Transplant; 2024 Apr; 43(4):652-662. PubMed ID: 38070662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.
    Tomlinson MG; Woods DB; McMahon M; Wahl MI; Witte ON; Kurosaki T; Bolen JB; Johnston JA
    BMC Immunol; 2001; 2():4. PubMed ID: 11410123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
    Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
    PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice.
    Kawata K; Hatano S; Baba A; Imabayashi K; Baba Y
    Front Immunol; 2024; 15():1388947. PubMed ID: 38638439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
    Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
    Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family.
    Shinners NP; Carlesso G; Castro I; Hoek KL; Corn RA; Woodland RT; Scott ML; Wang D; Khan WN
    J Immunol; 2007 Sep; 179(6):3872-80. PubMed ID: 17785824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
    Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
    Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells.
    Mahajan S; Vassilev A; Sun N; Ozer Z; Mao C; Uckun FM
    J Biol Chem; 2001 Aug; 276(33):31216-28. PubMed ID: 11413148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.
    Pontoriero M; Fiume G; Vecchio E; de Laurentiis A; Albano F; Iaccino E; Mimmi S; Pisano A; Agosti V; Giovannone E; Altobelli A; Caiazza C; Mallardo M; Scala G; Quinto I
    J Mol Med (Berl); 2019 May; 97(5):675-690. PubMed ID: 30887112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.
    Khan WN
    Immunol Res; 2001; 23(2-3):147-56. PubMed ID: 11444380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.